Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ: KPRX · Real-Time Price · USD
3.193
+0.003 (0.10%)
May 13, 2025, 4:00 PM - Market closed
Kiora Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 3.77 | 3.79 | 2.45 | 5.96 | 7.85 | 1.19 | Upgrade
|
Short-Term Investments | 20.33 | 23 | - | - | - | - | Upgrade
|
Cash & Short-Term Investments | 24.11 | 26.79 | 2.45 | 5.96 | 7.85 | 1.19 | Upgrade
|
Cash Growth | -22.93% | 991.47% | -58.85% | -24.06% | 562.47% | -68.61% | Upgrade
|
Accounts Receivable | 1.34 | 0.6 | - | - | - | - | Upgrade
|
Other Receivables | 0.72 | 0.27 | 2.05 | 1.37 | 0.53 | 0.09 | Upgrade
|
Receivables | 2.06 | 0.87 | 2.05 | 1.37 | 0.53 | 0.09 | Upgrade
|
Prepaid Expenses | 0.94 | 2.04 | 0.23 | 0.34 | 0.61 | 0.45 | Upgrade
|
Total Current Assets | 27.11 | 29.71 | 4.74 | 7.68 | 8.99 | 1.73 | Upgrade
|
Property, Plant & Equipment | 0.16 | 0.06 | 0.11 | 0.17 | 0.28 | 0.11 | Upgrade
|
Goodwill | - | - | - | - | - | 3.63 | Upgrade
|
Other Intangible Assets | 6.69 | - | 0.12 | 0.14 | 0.17 | 0.19 | Upgrade
|
Long-Term Deferred Charges | - | 6.69 | 8.7 | 10.6 | 10.6 | 9.54 | Upgrade
|
Other Long-Term Assets | 0.07 | 0.03 | 0.05 | 0.08 | 0.09 | 0.1 | Upgrade
|
Total Assets | 34.02 | 36.48 | 13.71 | 18.68 | 20.13 | 15.3 | Upgrade
|
Accounts Payable | 0.94 | 0.42 | 0.21 | 1.01 | 0.16 | 0.43 | Upgrade
|
Accrued Expenses | 3.52 | 2.26 | 1.38 | 1.84 | 1.33 | 1.29 | Upgrade
|
Current Portion of Long-Term Debt | - | - | - | - | - | 0.21 | Upgrade
|
Current Portion of Leases | 0.07 | 0.02 | 0.05 | 0.11 | 0.12 | 0.05 | Upgrade
|
Current Income Taxes Payable | - | 2.33 | - | - | - | - | Upgrade
|
Other Current Liabilities | 0.74 | 0.98 | - | 0.32 | - | - | Upgrade
|
Total Current Liabilities | 5.27 | 6.01 | 1.63 | 3.27 | 1.61 | 1.98 | Upgrade
|
Long-Term Debt | - | - | - | - | - | 0.28 | Upgrade
|
Long-Term Leases | 0.09 | 0.03 | 0.06 | - | 0.09 | 0.04 | Upgrade
|
Long-Term Deferred Tax Liabilities | 0.49 | 0.49 | 0.78 | 0.69 | 0.8 | 0.73 | Upgrade
|
Other Long-Term Liabilities | 4.47 | 4.19 | 5.13 | 3.31 | 3.05 | 2.55 | Upgrade
|
Total Liabilities | 10.32 | 10.72 | 7.6 | 7.27 | 5.55 | 5.57 | Upgrade
|
Common Stock | 0.27 | 0.27 | 0.08 | 0.02 | 0 | 0.06 | Upgrade
|
Additional Paid-In Capital | 169.3 | 169.16 | 153.19 | 146.04 | 135.54 | 116.78 | Upgrade
|
Retained Earnings | -145.58 | -143.38 | -146.98 | -134.46 | -120.88 | -107.11 | Upgrade
|
Comprehensive Income & Other | -0.3 | -0.28 | -0.18 | -0.18 | -0.09 | -0 | Upgrade
|
Total Common Equity | 23.7 | 25.76 | 6.11 | 11.41 | 14.58 | 9.73 | Upgrade
|
Shareholders' Equity | 23.7 | 25.76 | 6.11 | 11.41 | 14.58 | 9.73 | Upgrade
|
Total Liabilities & Equity | 34.02 | 36.48 | 13.71 | 18.68 | 20.13 | 15.3 | Upgrade
|
Total Debt | 0.16 | 0.06 | 0.11 | 0.11 | 0.21 | 0.57 | Upgrade
|
Net Cash (Debt) | 23.95 | 26.73 | 2.35 | 5.86 | 7.65 | 0.61 | Upgrade
|
Net Cash Growth | -23.20% | 1038.72% | -59.93% | -23.37% | 1150.70% | -83.45% | Upgrade
|
Net Cash Per Share | 5.69 | 6.48 | 4.36 | 72.00 | 285.39 | 47.93 | Upgrade
|
Filing Date Shares Outstanding | 3.04 | 3 | 2.92 | 0.21 | 0.04 | 0.02 | Upgrade
|
Total Common Shares Outstanding | 3 | 3 | 0.86 | 0.2 | 0.04 | 0.02 | Upgrade
|
Working Capital | 21.83 | 23.7 | 3.1 | 4.41 | 7.38 | -0.26 | Upgrade
|
Book Value Per Share | 7.90 | 8.58 | 7.14 | 57.15 | 414.44 | 630.41 | Upgrade
|
Tangible Book Value | 17.01 | 25.76 | 5.99 | 11.26 | 14.41 | 5.9 | Upgrade
|
Tangible Book Value Per Share | 5.67 | 8.58 | 7.00 | 56.43 | 409.64 | 382.58 | Upgrade
|
Machinery | - | 0.01 | 0.01 | 0.15 | 0.16 | 0.1 | Upgrade
|
Leasehold Improvements | - | - | - | 0.02 | 0.02 | 0.02 | Upgrade
|
Updated Mar 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.